Additional file 2 of Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study

Additional file 2. Figure S2: Kaplan–Meier survival analysis for OS in patients receiving adjuvant chemotherapy at stage II (A). DFS(B) and OS(C) in patients receiving adjuvant radiotherapy at stage I

Additional file 1 of Full-spectral genome analysis of natural killer/T cell lymphoma highlights impacts of genome instability in driving its progression

Additional file 1. Supplementary materials and methods

Additional file 4 of Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study

Additional file 4. Figure S4: Kaplan–Meier survival analysis for PFS (A) and OS (B) in patients receiving paclitaxel-based chemotherapy as first-line regimen at stage IV or after relapsed. PFS (C) and OS (D) in patients receiving gemcitabine-based chemotherapy as first-line regimen at stage IV or after relapsed. OS in patients at stage IV or after relapsed receiving radiotherapy (E

Additional file 1 of Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study

Additional file 1. Figure S1: Kaplan–Meier survival analysis for OS in patients receiving adjuvant chemotherapy at stage I (A). DFS(B) and OS(C) in patients receiving adjuvant radiotherapy at stage

Additional file 6 of Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study

Additional file 6. Figure S6: Kaplan–Meier survival analysis for OS according to ECOG PS≥2 (A), stage III-IV (B) , high level of EBV-DNA (C), liver metastasis (D) and bone metastasis (E

Additional file 5 of Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study

Additional file 5. Figure S5: Kaplan–Meier survival analysis for OS in patients receiving anti- angiogenesis (A) and anti- EGFR (B) therapy at stage IV or after relapsed. Kaplan–Meier survival analysis for PFS in patients receiving anti-angiogenesis (C) and anti-EGFR (D) therapy at stage IV or after relapse

Additional file 3 of Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study

Additional file 3 Supplement Figure 3 Kaplan–Meier survival analysis for OS in patients receiving adjuvant radiotherapy at stage III (A). DFS(B) and OS(C) in patients receiving adjuvant chemotherapy at stage II